Higher susceptibility of NOD/LtSz-Scid Il2rg-/- NSG mice to xenotransplanted lung cancer cell lines

Cancer Management and Research

Volumn 6, Issue , 2014, Pages 431-436

  Kanaji, Nobuhiro ^a   Tadokoro, Akira ^a   Susaki, Kentaro ^a   Yokokura, Saki ^a   Ohmichi, Kiyomi ^b   Haba, Reiji ^b   Watanabe, Naoki ^a   Bandoh, Shuji ^a   Ishii, Tomoya ^a   Dobashi, Hiroaki ^a   Matsunaga, Takuya ^a  

^a Department of Diagnostic Pathology Kagawa University ^*

^b KAGAWA UNIVERSITY   (Japan)

Author keywords

Mouse model; NOD scid Il2rg(null); Tumorigenicity; Xenograft; Xenotransplantation

Indexed keywords

A549 CELL LINE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SUSCEPTIBILITY; CARCINOGENICITY; CONTROLLED STUDY; EBC1 CELL LINE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG CANCER; LUNG CANCER CELL LINE; MOUSE; MOUSE STRAIN; NOD SCID GAMMA MOUSE; NOD SCID MOUSE; NONHUMAN; NUDE MOUSE; SCID MOUSE; STRAIN DIFFERENCE; TUMOR CELL INOCULATION; TUMOR VOLUME; XENOTRANSPLANTATION;

EID: 84908290704     PISSN: None     EISSN: 11791322     Source Type: Journal    
DOI: 10.2147/CMAR.S71185     Document Type: Article

References (33)

1. Sartelet H, Durrieu L, Fontaine F, Nyalendo C, Haddad E. Description of a new xenograft model of metastatic neuroblastoma using NOD/SCID/Il2rg null (NSG) mice. In Vivo. 2012;26(1):19-29.
2. Shultz LD, Ishikawa F, Greiner DL. Humanized mice in translational biomedical research. Nat Rev Immunol. 2007;7(2):118-130.
3. Wen QL, Meng MB, Yang B, et al. Endostar, a recombined humanized endostatin, enhances the radioresponse for human nasopharyngeal carcinoma and human lung adenocarcinoma xenografts in mice. Cancer Sci. 2009;100(8):1510-1519.
4. Navab R, Strumpf D, Bandarchi B, et al. Prognostic gene-expression signature of carcinoma-associated fibroblasts in non-small cell lung cancer. Proc Natl Acad Sci U S A. 2011;108(17):7160-7165.
5. John T, Kohler D, Pintilie M, et al. The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in early-stage non-small cell lung cancer. Clin Cancer Res. 2011;17(1): 134-141.
6. Daniel VC, Marchionni L, Hierman JS, et al. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res. 2009;69(8):3364-3373.
7. Merk J, Rolff J, Becker M, Leschber G, Fichtner I. Patient-derived xenografts of non-small-cell lung cancer: a pre-clinical model to evaluate adjuvant chemotherapy? Eur J Cardiothorac Surg. 2009;36(3): 454-459.
8. Sugamura K, Asao H, Kondo M, et al. The interleukin-2 receptor gamma chain: its role in the multiple cytokine receptor complexes and T cell development in XSCID. Annu Rev Immunol. 1996;14:179-205.
9. Ohbo K, Suda T, Hashiyama M, et al. Modulation of hematopoiesis in mice with a truncated mutant of the interleukin-2 receptor gamma chain. Blood. 1996;87(3):956-967.
10. Cao X, Shores EW, Hu-Li J, et al. Defective lymphoid development in mice lacking expression of the common cytokine receptor gamma chain. Immunity. 1995;2(3):223-238.
11. DiSanto JP, Müller W, Guy-Grand D, Fischer A, Rajewsky K. Lymphoid development in mice with a targeted deletion of the interleukin 2 receptor gamma chain. Proc Natl Acad Sci U S A. 1995;92(2):377-381.
12. Machida K, Suemizu H, Kawai K, et al. Higher susceptibility of NOG mice to xenotransplanted tumors. J Toxicol Sci. 2009;34(1):123-127.
13. Suemizu H, Monnai M, Ohnishi Y, Ito M, Tamaoki N, Nakamura M. Identification of a key molecular regulator of liver metastasis in human pancreatic carcinoma using a novel quantitative model of metastasis in NOD/SCID/gammacnull (NOG) mice. Int J Oncol. 2007;31(4): 741-751.
14. Miyakawa Y, Ohnishi Y, Tomisawa M, et al. Establishment of a new model of human multiple myeloma using NOD/SCID/gammac(null) (NOG) mice. Biochem Biophys Res Commun. 2004;313(2):258-262.
15. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ. Efficient tumour formation by single human melanoma cells. Nature. 2008;456(7222):593-598.
16. Agliano A, Martin-Padura I, Mancuso P, et al. Human acute leukemia cells injected in NOD/LtSz-scid/IL-2Rgamma null mice generate a faster and more efficient disease compared to other NOD/scid-related strains. Int J Cancer. 2008;123(9):2222-2227.
17. Kanaji N, Bandoh S, Fujita J, Ishii T, Ishida T, Kubo A. Compensation of type I and type II cytokeratin pools in lung cancer. Lung Cancer. 2007;55(3):295-302.
18. Fogh J, Fogh JM, Orfeo T. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J Natl Cancer Inst. 1977;59(1):221-226.
19. Jones AM, Hanson IM, Armstrong GR, O'Driscoll BR. Value and accuracy of cytology in addition to histology in the diagnosis of lung cancer at flexible bronchoscopy. Respir Med. 2001;95:374-378.
20. Datta D, Lahiri B. Preoperative evaluation of patients undergoing lung resection surgery. Chest. 2003;123:2096-2103.
21. Oie HK, Russell EK, Carney DN, Gazdar AF. Cell culture methods for the establishment of the NCI series of lung cancer cell lines. J Cell Biochem Suppl. 1996;24:24-31.
22. Zhang X, Claerhout S, Prat A, et al. A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res. 2013;73(15):4885-4897.
23. Gandara DR, Li T, Lara PN Jr, et al. Algorithm for codevelopment of new drug-predictive biomarker combinations: accounting for inter- and intrapatient tumor heterogeneity. Clin Lung Cancer. 2012;13(5):321-325.
24. Metelitsa LS, Naidenko OV, Kant A, et al. Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells. J Immunol. 2001;167(6):3114-3122.
25. Agah R, Malloy B, Sherrod A, Bean P, Girgis E, Mazumder A. Therapy of disseminated NK-resistant tumor by the synergistic effects of recombinant interleukin-2 and tumor necrosis factor. J Biol Response Mod. 1988;7(2):140-151.
26. Lala PK, Elkashab M, Kerbel RS, Parhar RS. Cure of human melanoma lung metastases in nude mice with chronic indomethacin therapy combined with multiple rounds of IL-2: characteristics of killer cells generated in situ. Int Immunol. 1990;2(12):1149-1158.
27. Itoh K, Tilden AB, Balch CM. Lysis of human solid tumor cells by lymphokine-activated natural killer cells. J Immunol. 1986;136(10):3910-3915.
28. Robinson BW, Morstyn G. Natural killer (NK)-resistant human lung cancer cells are lysed by recombinant interleukin-2-activated NK cells. Cell Immunol. 1987;106(2):215-222.
29. Stein-Streilein J, Guffee J, Ramos M, Pitchenik AE. Spontaneous lymphokine activated killer (LAK) activity in bronchoalveolar lavage cells from patients with bronchogenic carcinoma. Reg Immunol. 1989;2(6):370-375.
30. Pitchenik AE, Guffee J, Stein-Streilein J. Lung natural killer and interleukin-2 activity in lung cancer. A pulmonary compartment of augmented natural killer activity occurs in patients with bronchogenic carcinoma. Am Rev Respir Dis. 1987;136(6):1327-1332.
31. Esendagli G, Bruderek K, Goldmann T, et al. Malignant and non-malignant lung tissue areas are differentially populated by natural killer cells and regulatory T cells in non-small cell lung cancer. Lung Cancer. 2008;59(1):32-40.
32. Matsumori Y, Yano S, Goto H, et al. ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model. Oncol Res. 2006;16(1):15-26.
33. Cui R, Yoshioka M, Takahashi F, Ishida H, Iwakami S, Takahashi K. Vinorelbine is effective for the malignant pleural effusion associated with lung cancer in mice. Anticancer Res. 2008;28(3A):1633-1639.